26/01/2009 Alma Lasers Announces FDA clearance of the UniForm Handpiece

Alma Lasers Ltd a leader in laser, light and radiofrequency-based aesthetic devices, announced today the FDA clearance and immediate availability of the UniForm handpiece.

03/09/2008 Combination of a New Radiofrequency Device and Blue Light For the Treatment of Acne Vulgaris

This case report describes the efficacy and safety of RF energy (Accent, Alma Lasers Inc, Buffalo Grove, IL) and blue light (BLU-U, Dusa Pharmaceuticals, Inc, Wilmington, MA) used in combination to treat grade 4 cystic acne and acne scars in an Asian woman of skin type IV.

15/04/2008 Alma CEO - Letter to our customers

I write to address some recent reports of litigation activity between Alma Lasers and Lumenis.

26/03/2008 U.S. PTO Rexamining Lumenis Patents

Alma Lasers Ltd, a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL.

02/01/2008 Alma Lasers to Debut Five New Products at AAD

Alma Lasers Ltd., a global developer and marketer of laser, intense pulsed light, and radiofrequency-based aesthetic devices, announced today that it will unveil five new products at the 66th Annual Meeting of the American Academy of Dermatology (AAD).

30/04/2007 Alam Lasers Receives FDA Clearance For The Accent Dual Mode RF System

Alma Lasers a global leader in laser, light-based, and radio frequency (RF) technologies used in aesthetic medicine announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the Accent Dual Mode RF System in the United States.

04/03/2006 Alma Lasers Announces $90 Million Investment by TA Associates

TA Associates, a leading private equity and buyout firm, today announced it has completed a $90 million investment in Alma Lasers, Ltd., a developer, manufacturer and marketer of laser, light and radiofrequency-based systems for the aesthetic medical market.

< Back